APOE and Alzheimer disease: We evaluated the differences in plasma AD-biomarker levels (i.e., Aβ1−42, Aβ1−40, and APP669−711) between the PA groups in all participants and after stratifying by APOE ε4 carriage status or brain amyloid status (Table 2).